Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin

Pflugers Archiv European Journal of Physiology

Volumn 466, Issue 8, 2014, Pages 1591-1604

  Mekahli, Djalila ^a,b   Decuypere, Jean Paul ^a   Sammels, Eva ^a   Welkenhuyzen, Kirsten ^a   Schoeber, Joost ^a   Audrezet, Marie Pierre ^c   Corvelyn, Anniek ^a   Dechênes, Georges ^d   Ong, Albert C M ^e   Wilmer, Martijn J ^f   Van Den Heuvel, Lambertus ^a,f   Bultynck, Geert ^a   Parys, Jan B ^a   Missiaen, Ludwig ^a   Levtchenko, Elena ^a,b   De Smedt, Humbert ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c BREST UNIVERSITY HOSPITAL   (France)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADPKD; Metformin; mTOR; Rapamycin

Indexed keywords

METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; POLYCYSTIN 1; RAPAMYCIN; SMALL INTERFERING RNA; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; POLYCYSTIC KIDNEY DISEASE 2 PROTEIN; POLYCYSTIN; TARGET OF RAPAMYCIN KINASE;

ADOLESCENT; ADULT; ARTICLE; CELL PROLIFERATION; CELL VIABILITY ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENE OVEREXPRESSION; GENETIC SCREENING; HUMAN; IMMUNOBLOTTING; KIDNEY CELL; KIDNEY POLYCYSTIC DISEASE; LOSS OF FUNCTION MUTATION; MALE; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UPREGULATION; ANIMAL; DEFICIENCY; DRUG EFFECTS; GENE SILENCING; GENETICS; METABOLISM; MOUSE; MUTATION;

ANIMALS; DRUG SYNERGISM; GENE KNOCKDOWN TECHNIQUES; HUMANS; METFORMIN; MICE; MUTATION; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRPP CATION CHANNELS; UP-REGULATION;

EID: 84904255707     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-013-1394-x     Document Type: Article

References (59)

1. Audrezet MP, Cornec-Le Gall E, Chen JM, Redon S, Quere I, Creff J, Benech C, Maestri S, Le Meur Y, Ferec C (2012) Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients. Hum Mutat 33(8):1239-1250
2. Barua M, Cil O, Paterson AD, Wang K, He N, Dicks E, Parfrey P, Pei Y (2009) Family history of renal disease severity predicts themutated gene in ADPKD. J Am Soc Nephrol 20(8):1833-1838
3. Boletta A (2009) Emerging evidence of a link between the polycystins and the mTOR pathways. Pathogenetics 2(1):6
4. Canaud G, Knebelmann B, Harris PC, Vrtovsnik F, Correas JM, Pallet N, Heyer CM, Letavernier E, Bienaime F, Thervet E, Martinez F, Terzi F, Legendre C (2010) Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level? Am J Transplant 10(7):1701-1706
5. Chang MY, Ong AC (2012) Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clin Pract 120(1):c25-34, discussion c35
6. Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF Jr, Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP (2003) Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 64(3):1035-1045 (Pubitemid 37013840)
7. Chung W, Kim H, Hwang YH, Kim SY, Ko AR, Ro H, Lee KB, Lee JS, Oh KH, Ahn C (2006) PKD2 gene mutation analysis in Korean autosomal dominant polycystic kidney disease patients using two-dimensional gene scanning. Clin Genet 70(6):502-508 (Pubitemid 44741472)
8. Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek KB, Germino GG, Pandolfi PP, Boletta A (2009) Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 29(9):2359-2371
9. Frid A, Sterner GN, Londahl M, Wiklander C, Cato A, Vinge E, Andersson A (2010) Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care 33(6):1291-1293
10. Giamarchi A, Feng S, Rodat-Despoix L, Xu Y, Bubenshchikova E, Newby LJ, Hao J, Gaudioso C, Crest M, Lupas AN, Honore E, Williamson MP, Obara T, Ong AC, Delmas P (2010) A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J 29(7):1176-1191
11. Grantham JJ, Bennett WM, Perrone RD (2011) mTOR inhibitors and autosomal dominant polycystic kidney disease.N Engl JMed 364(3):286-287, author reply 287-289
12. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP (2006) Volume progression in polycystic kidney disease. N Engl J Med 354(20):2122-2130 (Pubitemid 43736612)
13. Habib SL (2011) Mechanism of activation of AMPK and upregulation of OGG1 by rapamycin in cancer cells. Oncotarget 2(12):958-959
14. Habib SL, Kasinath BS, Arya RR, Vexler S, Velagapudi C (2010) Novel mechanism of reducing tumourigenesis: upregulation of the DNA repair enzyme OGG1 by rapamycin-mediated AMPK activation and mTOR inhibition. Eur J Cancer 46(15):2806-2820
15. Hanaoka K, Qian F, Boletta A, Bhunia AK, Piontek K, Tsiokas L, Sukhatme VP, Guggino WB, Germino GG (2000) Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 408(6815):990-994 (Pubitemid 32101647)
16. Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, Guay-Woodford LM, King BF, Wetzel LH, Baumgarten DA, Kenney PJ, Consugar M, Klahr S, Bennett WM, Meyers CM, Zhang QJ, Thompson PA, Zhu F, Miller JP (2006) Cyst number but not the rate of cystic growth is associated with themutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 17(11):3013-3019 (Pubitemid 44707761)
17. Hartman TR, Liu D, Zilfou JT, Robb V, Morrison T, Watnick T, Henske EP (2009) The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. Hum Mol Genet 18(1):151-163
18. Hateboer N, Van Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, Torra R, Breuning M, Ravine D (1999) Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 353(9147):103-107 (Pubitemid 29088079)
19. Huang J, Manning BD (2008) The TSC1 - TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412(2):179-190 (Pubitemid 351758225)
20. Iyer S, Deutsch K, Yan X, Lin B (2007) Batch RNAi selector: a standalone program to predict specific siRNA candidates in batches with enhanced sensitivity. Comput Methods Programs Biomed 85(3):203-209 (Pubitemid 46241598)
21. Karcher C, Fischer A, Schweickert A, Bitzer E, Horie S, Witzgall R, Blum M (2005) Lack of a laterality phenotype in Pkd1 knock-out embryos correlates with absence of polycystin-1 in nodal cilia. Differentiation 73(8):425-432
22. Lieberthal W, Levine JS (2012) Mammalian target of rapamycin and the kidney part I: the signaling pathway. Am J Physiol Renal Physiol 303(301):301-310
23. Lieberthal W, Levine JS (2012) Mammalian target of rapamycin and the kidney part II: pathophysiology and therapeutic implications. Am J Physiol Renal Physiol 303(302):180-391
24. Lipska KJ, Bailey CJ, Inzucchi SE (2011) Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 34(6):1431-1437
25. McCarty MF, Barroso-Aranda J, Contreras F (2009) Activation of AMP-activated kinase as a strategy for managing autosomal dominant polycystic kidney disease. Med Hypotheses 73(6):1008-1010
26. Mekahli D, Sammels E, Luyten T, Welkenhuyzen K, van den Heuvel LP, Levtchenko EN, Gijsbers R, Bultynck G, Parys JB, De Smedt H, Missiaen L (2012) Polycystin-1 and polycystin-2 are both required to amplify inositol- trisphosphate-induced Ca(2+) release. Cell Calcium 51(6):452-458
27. Novalic Z, van der Wal AM, Leonhard WN, Koehl G, Breuning MH, Geissler EK, de Heer E, Peters DJ (2012) Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 23(5):842-853
28. Ong AC, Harris PC, Biddolph S, Bowker C, Ward CJ (1999) Characterisation and expression of the PKD-1 protein, polycystin, in renal and extrarenal tissues. Kidney Int 55(5):2091-2116
29. Ong AC, Harris PC, Davies DR, Pritchard L, Rossetti S, Biddolph S, Vaux DJ, Migone N, Ward CJ (1999) Polycystin-1 expression in PKD1, early-onset PKD1, and TSC2/PKD1 cystic tissue. Kidney Int 56(4):1324-1333 (Pubitemid 29451240)
30. Ong AC, Ward CJ, Butler RJ, Biddolph S, Bowker C, Torra R, Pei Y, Harris PC (1999) Coordinate expression of the autosomal dominant polycystic kidney disease proteins, polycystin-2 and polycystin-1, in normal and cystic tissue. Am J Pathol 154(6):1721-1729 (Pubitemid 29262854)
31. Peral B, Gamble V, Strong C, Ong AC, Sloane-Stanley J, Zerres K, Winearls CG, Harris PC (1997) Identification of mutations in the duplicated region of the polycystic kidney disease 1 gene (PKD1) by a novel approach. Am J Hum Genet 60(6):1399-1410 (Pubitemid 27258072)
32. Perico N, Remuzzi G (2010) Do mTOR inhibitors still have a future in ADPKD? Nat Rev Nephrol 6(12):696-698
33. Peters N, Jay N, Barraud D, Cravoisy A, Nace L, Bollaert PE, Gibot S (2008) Metformin-associated lactic acidosis in an intensive care unit. Crit Care 12(6):R149
34. Ponticelli C, Locatelli F (2010) Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment. Nephrol Dial Transplant 25(12):3809-3812
35. Qian F, Germino FJ, Cai Y, Zhang X, Somlo S, Germino GG (1997) PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 16(2):179-183 (Pubitemid 27240617)
36. Qian Q, Du H, King BF, Kumar S, Dean PG, Cosio FG, Torres VE (2008) Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 19(3):631-638 (Pubitemid 351355407)
37. Roelfsema JH, Spruit L, Saris JJ, Chang P, Pirson Y, van Ommen GJ, Peters DJ, Breuning MH (1997) Mutation detection in the repeated part of the PKD1 gene. Am J Hum Genet 61(5):1044-1052 (Pubitemid 27492311)
38. Rossetti S, Hopp K, Sikkink RA, Sundsbak JL, Lee YK, Kubly V, Eckloff BW, Ward CJ, Winearls CG, Torres VE, Harris PC (2012) Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol 23(5):915-933
39. Sammels E, Devogelaere B, Mekahli D, Bultynck G, Missiaen L, Parys JB, Cai Y, Somlo S, De Smedt H (2010) Polycystin-2 activation by inositol 1,4,5-trisphosphate-induced Ca2+ release requires its direct association with the inositol 1,4,5-trisphosphate receptor in a signaling microdomain. J Biol Chem 285(24):18794-18805
40. Sarbassov DD, Ali SM, Sabatini DM (2005) Growing roles for the mTOR pathway. Curr Opin Cell Biol 17(6):596-603 (Pubitemid 41540408)
41. Schrier RW (2010) Randomized intervention studies in human polycystic kidney and liver disease. J Am Soc Nephrol 21(6):891-893
42. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wuthrich RP (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363(9):820-829
43. Shaw RJ (2009) LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 196(1):65-80
44. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103(14):5466-5471
45. Shillingford JM, Piontek KB, Germino GG, Weimbs T (2010) Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 21(3):489-497
46. Takiar V, Nishio S, Seo-Mayer P, King JD Jr, Li H, Zhang L, Karihaloo A, Hallows KR, Somlo S, Caplan MJ (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A 108(6):2462-2467
47. Tao Y, Kim J, Schrier RW, Edelstein CL (2005) Rapamycinmarkedly slows disease progression in a ratmodel of polycystic kidney disease. J Am Soc Nephrol 16(1):46-51 (Pubitemid 43073155)
48. Torra R, Badenas C, Perez-Oller L, Luis J, Millan S, Nicolau C, Oppenheimer F, Mila M, Darnell A (2000) Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients. Am J Kidney Dis 36(4):728-734
49. Torres VE, Harris PC (2009) Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 76(2):149-168
50. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP (2006) Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21(3):598-604 (Pubitemid 43372904)
51. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Horl WH, Obermuller N, Arns W, Pavenstadt H, Gaedeke J, Buchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363(9):830-840
52. Watnick T, Germino GG (2010) mTOR inhibitors in polycystic kidney disease. N Engl J Med 363(9):879-881
53. Wilmer MJ, Saleem MA, Masereeuw R, Ni L, van der Velden TJ, Russel FG, Mathieson PW, Monnens LA, van den Heuvel LP, Levtchenko EN (2010) Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res 339(2):449-457
54. Wu G, D'Agati V, Cai Y, Markowitz G, Park JH, Reynolds DM, Maeda Y, Le TC, Hou H Jr, Kucherlapati R, Edelmann W, Somlo S (1998) Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93(2):177-188 (Pubitemid 28180852)
55. Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wuthrich RP, Serra AL (2009) Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol 297(6):F1597-1605
56. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124(3):471-484 (Pubitemid 43199434)
57. Yu Y, Ulbrich MH, Li MH, Buraei Z, Chen XZ, Ong AC, Tong L, Isacoff EY, Yang J (2009) Structural and molecular basis of the assembly of the TRPP2/PKD1 complex. Proc Natl Acad Sci U S A 106(28):11558-11563
58. Zafar I, Belibi FA, He Z, Edelstein CL (2009) Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 24(8):2349-2353
59. Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL (2010) Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int 78(8):754-761